The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Phenotypic Heterogeneity among Tumorigenic Melanoma Cells from Patients that Is Reversible and Not Hierarchically Organized
Open accessAbstract
Summary We investigated whether melanoma is hierarchically organized into phenotypically distinct subpopulations of tumorigenic and non-tumorigenic cells, or whether most melanoma cells retain tumorigenic capacity, irrespective of their phenotype. We found 28% of single melanoma cells obtained directly from patients formed tumors in NOD/SCID IL2Rγnull mice. All stage II, III, and IV melanomas obtained directly from patients had common tumorigenic cells. All tumorigenic cells appeared to have unlimited tumorigenic capacity upon serial transplantation. We were unable to find any large subpopulation of melanoma cells that lacked tumorigenic potential. None of 22 heterogeneously-expressed markers, including CD271 and ABCB5, enriched tumorigenic cells. Some melanomas metastasized in mice, irrespective of whether they arose from CD271- or CD271+ cells. Many markers appeared to be reversibly expressed by tumorigenic melanoma cells. Significance In cancers that follow a stem cell model, phenotypically distinct tumorigenic cells form abundant and phenotypically diverse non-tumorigenic progeny in a hierarchical manner that resembles normal stem cell differentiation. In contrast to this model, our results indicate that primary cutaneous or metastatic melanomas from patients have common and phenotypically diverse tumorigenic cells that undergo reversible phenotypic changes in vivo. Most of the phenotypic heterogeneity in melanoma is therefore not associated with a loss of tumorigenic potential or organized in stable hierarchies. These data suggest a phenotypic plasticity model in which phenotypic heterogeneity is driven largely by reversible changes within lineages of tumorigenic cells rather than by irreversible epigenetic or genetic changes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prospective identification of tumorigenic breast cancer cells
Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J., & Clarke, M. F. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0530291100 · Cited by 10,370
Self-citationStem cells, cancer, and cancer stem cells
Reya, T., Morrison, S. J., Clarke, M. F., & Weissman, I. L. (2001) · Nature · doi:10.1038/35102167 · Cited by 9,738
Self-citationThe Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells
Mani, S. A., Guo, W., Liao, M.-J., Eaton, E. N., Ayyanan, A., Zhou, A. Y., Brooks, M., Reinhard, F., Zhang, C. C., Shipitsin, M., et al. (2008) · Cell · doi:10.1016/j.cell.2008.03.027 · Cited by 8,672
Identification of human brain tumour initiating cells
Singh, S. K., Hawkins, C., Clarke, I. D., Squire, J. A., Bayani, J., Hide, T., Henkelman, R. M., Cusimano, M. D., & Dirks, P. B. (2004) · Nature · doi:10.1038/nature03128 · Cited by 7,433
Nowell, P. C. (1976) · Science · doi:10.1126/science.959840 · Cited by 6,471
Bonnet, D., & Dick, J. E. (1997) · Nature Medicine · doi:10.1038/nm0797-730 · Cited by 5,864
A cell initiating human acute myeloid leukaemia after transplantation into SCID mice
Lapidot, T., Sirard, C., Vormoor, J., Murdoch, B., Hoang, T., Caceres-Cortes, J., Minden, M., Paterson, B., Caligiuri, M. A., & Dick, J. E. (1994) · Nature · doi:10.1038/367645a0 · Cited by 4,783 · cited 8×
“Cancer stem cell studies have consistently found that cells from nontumorigenic/nonleukemogenic cancer cell populations are rarely able to form tumors/leukemias, even when assayed under conditions permissive for tumorigenesis by small numbers of cancer stem cells (Al-Hajj et al., 2003; Bonnet and Dick, 1997; Lapidot e…”
BackgroundResultInfluentialA human colon cancer cell capable of initiating tumour growth in immunodeficient mice
O’Brien, C. A., Pollett, A., Gallinger, S., & Dick, J. E. (2007) · Nature · doi:10.1038/nature05372 · Cited by 4,087
Identification and expansion of human colon-cancer-initiating cells
Ricci-Vitiani, L., Lombardi, D. G., Pilozzi, E., Biffoni, M., Todaro, M., Peschle, C., & De Maria, R. (2007) · Nature · doi:10.1038/nature05384 · Cited by 3,998
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., McDermott, U., Azizian, N., Zou, L., Fischbach, M. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.027 · Cited by 2,770
Cited by
Tumour heterogeneity and cancer cell plasticity
Meacham, C. E., & Morrison, S. J. (2013) · Nature · doi:10.1038/nature12624 · Cited by 2,446
Self-citationEvolution of the Cancer Stem Cell Model
Kreso, A., & Dick, J. E. (2014) · Cell Stem Cell · doi:10.1016/j.stem.2014.02.006 · Cited by 2,224
The cancer stem cell: premises, promises and challenges
Clevers, H. (2011) · Nature Medicine · doi:10.1038/nm.2304 · Cited by 1,923
Targeting cancer stem cell pathways for cancer therapy
Yang, L., Shi, P., Zhao, G., Xu, J., Peng, W., Zhang, J., Zhang, G., Wang, X., Dong, Z., Chen, F., et al. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0110-5 · Cited by 1,906
Cancer Stem Cells: Current Status and Evolving Complexities
Visvader, J. E., & Lindeman, G. J. (2012) · Cell Stem Cell · doi:10.1016/j.stem.2012.05.007 · Cited by 1,287
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
Wilson, T. R., Fridlyand, J., Yan, Y., Penuel, E., Burton, L., Chan, E., Peng, J., Lin, E., Wang, Y., Sosman, J., et al. (2012) · Nature · doi:10.1038/nature11249 · Cited by 1,134
Cancer Stem Cells: Impact, Heterogeneity, and Uncertainty
Magee, J. A., Piskounova, E., & Morrison, S. J. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.03.003 · Cited by 1,101
Self-citationOncogenic roles of EMT-inducing transcription factors
Puisieux, A., Brabletz, T., & Caramel, J. (2014) · Nature Cell Biology · doi:10.1038/ncb2976 · Cited by 1,040
Heterogeneity in breast cancer
Polyak, K. (2011) · Journal of Clinical Investigation · doi:10.1172/jci60534 · Cited by 1,006
Unravelling cancer stem cell potential
Beck, B., & Blanpain, C. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3597 · Cited by 905
Cancer Stem Cells: Basic Concepts and Therapeutic Implications
Nassar, D., & Blanpain, C. (2016) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012615-044438 · Cited by 869
Mechanisms of chemoresistance in cancer stem cells
Abdullah, L. N., & Chow, E. K. (2013) · Clinical and Translational Medicine · doi:10.1186/2001-1326-2-3 · Cited by 721
Metastatic Stem Cells: Sources, Niches, and Vital Pathways
Oskarsson, T., Batlle, E., & Massagué, J. (2014) · Cell Stem Cell · doi:10.1016/j.stem.2014.02.002 · Cited by 708
Cancer stem cell definitions and terminology: the devil is in the details
Valent, P., Bonnet, D., De Maria, R., Lapidot, T., Copland, M., Melo, J. V., Chomienne, C., Ishikawa, F., Schuringa, J. J., Stassi, G., et al. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3368 · Cited by 692
Zhang, W. C., Shyh-Chang, N., Yang, H., Rai, A., Umashankar, S., Ma, S., Soh, B. S., Sun, L. L., Tai, B. C., Nga, M. E., et al. (2012) · Cell · doi:10.1016/j.cell.2011.11.050 · Cited by 660
Plasticity of epithelial stem cells in tissue regeneration
Blanpain, C., & Fuchs, E. (2014) · Science · doi:10.1126/science.1242281 · Cited by 589
Cancer Stem Cells: The Architects of the Tumor Ecosystem
Prager, B. C., Xie, Q., Bao, S., & Rich, J. N. (2019) · Cell Stem Cell · doi:10.1016/j.stem.2018.12.009 · Cited by 587
Lee, S. Y., Jeong, E. K., Ju, M. K., Jeon, H. M., Kim, M. Y., Kim, C. H., Park, H. G., Han, S. I., & Kang, H. S. (2017) · Molecular Cancer · doi:10.1186/s12943-016-0577-4 · Cited by 578
Cancer stem cells: advances in knowledge and implications for cancer therapy
Chu, X., Tian, W., Ning, J., Xiao, G., Zhou, Y., Wang, Z., Zhai, Z., Tanzhu, G., Yang, J., & Zhou, R. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01851-y · Cited by 553
Dirkse, A., Golebiewska, A., Buder, T., Nazarov, P. V., Muller, A., Poovathingal, S., Brons, N. H. C., Leite, S., Sauvageot, N., Sarkisjan, D., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09853-z · Cited by 529
Isolation and characterization of extracellular vesicle subpopulations from tissues
Crescitelli, R., Lässer, C., & Lötvall, J. (2021) · Nature Protocols · doi:10.1038/s41596-020-00466-1 · Cited by 507
Lin28: Primal Regulator of Growth and Metabolism in Stem Cells
Shyh-Chang, N., & Daley, G. Q. (2013) · Cell Stem Cell · doi:10.1016/j.stem.2013.03.005 · Cited by 458
The evolving concept of cancer and metastasis stem cells
Baccelli, I., & Trumpp, A. (2012) · Journal of Cell Biology · doi:10.1083/jcb.201202014 · Cited by 412
Cancer Stem Cell Quiescence and Plasticity as Major Challenges in Cancer Therapy
Chen, W., Dong, J., Haiech, J., Kilhoffer, M.-C., & Zeniou, M. (2016) · Stem Cells International · doi:10.1155/2016/1740936 · Cited by 402
Phenotype plasticity as enabler of melanoma progression and therapy resistance
Arozarena, I., & Wellbrock, C. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0154-4 · Cited by 381
Targeting the Notch-regulated non-coding RNA TUG1 for glioma treatment
Katsushima, K., Natsume, A., Ohka, F., Shinjo, K., Hatanaka, A., Ichimura, N., Sato, S., Takahashi, S., Kimura, H., Totoki, Y., et al. (2016) · Nature Communications · doi:10.1038/ncomms13616 · Cited by 352
Cancer stem cell surface markers on normal stem cells
Kim, W.-T., & Ryu, C. J. (2017) · BMB Reports · doi:10.5483/bmbrep.2017.50.6.039 · Cited by 332
Civenni, G., Walter, A., Kobert, N., Mihic-Probst, D., Zipser, M., Belloni, B., Seifert, B., Moch, H., Dummer, R., van den Broek, M., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3997 · Cited by 326
Melanoma plasticity and phenotypic diversity: therapeutic barriers and opportunities
Rambow, F., Marine, J.-C., & Goding, C. R. (2019) · Genes & Development · doi:10.1101/gad.329771.119 · Cited by 325
Reactive Oxygen Species in Cancer Stem Cells
Shi, X., Zhang, Y., Zheng, J., & Pan, J. (2012) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.4529 · Cited by 325
Intra-tumor heterogeneity of cancer cells and its implications for cancer treatment
Sun, X.-X., & Yu, Q. (2015) · Acta Pharmacologica Sinica · doi:10.1038/aps.2015.92 · Cited by 318
Acquired cancer stem cell phenotypes through Oct4-mediated dedifferentiation
Kumar, S. M., Liu, S., Lu, H., Zhang, H., Zhang, P. J., Gimotty, P. A., Guerra, M., Guo, W., & Xu, X. (2012) · Oncogene · doi:10.1038/onc.2011.656 · Cited by 308
Vanner, R. J., Remke, M., Gallo, M., Selvadurai, H. J., Coutinho, F., Lee, L., Kushida, M., Head, R., Morrissy, S., Zhu, X., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.05.005 · Cited by 305
Ganglioside GD2 identifies breast cancer stem cells and promotes tumorigenesis
Battula, V. L., Shi, Y., Evans, K. W., Wang, R.-Y., Spaeth, E. L., Jacamo, R. O., Guerra, R., Sahin, A. A., Marini, F. C., Hortobagyi, G., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59735 · Cited by 302
Grosse‐Gehling, P., Fargeas, C. A., Dittfeld, C., Garbe, Y., Alison, M. R., Corbeil, D., & Kunz‐Schughart, L. A. (2013) · The Journal of Pathology · doi:10.1002/path.4086 · Cited by 301
Intratumor and Intertumor Heterogeneity in Melanoma
Grzywa, T. M., Paskal, W., & Włodarski, P. K. (2017) · Translational Oncology · doi:10.1016/j.tranon.2017.09.007 · Cited by 299
Distinct types of tumor-initiating cells form human colon cancer tumors and metastases
Dieter, S. M., Ball, C. R., Hoffmann, C. M., Nowrouzi, A., Herbst, F., Zavidij, O., Abel, U., Arens, A., Weichert, W., Brand, K., et al. (2011) · Cell stem cell · doi:10.1016/j.stem.2011.08.010 · Cited by 297
Drug rechallenge and treatment beyond progression—implications for drug resistance
Kuczynski, E. A., Sargent, D. J., Grothey, A., & Kerbel, R. S. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.158 · Cited by 286
ALDH1A Isozymes are Markers of Human Melanoma Stem Cells and Potential Therapeutic Targets
Luo, Y., Dallaglio, K., Chen, Y., Robinson, W. A., Robinson, S. E., McCarter, M. D., Wang, J., Gonzalez, R., Thompson, D. C., Norris, D. A., et al. (2012) · Stem Cells · doi:10.1002/stem.1193 · Cited by 281
Cancer stem cells: A review from origin to therapeutic implications
Atashzar, M. R., Baharlou, R., Karami, J., Abdollahi, H., Rezaei, R., Pourramezan, F., & Zoljalali Moghaddam, S. H. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.29044 · Cited by 281
Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance?
Hölzel, M., Bovier, A., & Tüting, T. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3498 · Cited by 269
Cancer stem cells and their role in metastasis
Shiozawa, Y., Nie, B., Pienta, K. J., Morgan, T. M., & Taichman, R. S. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.01.014 · Cited by 268
Tumors and Mitochondrial Respiration: A Neglected Connection
Viale, A., Corti, D., & Draetta, G. F. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0491 · Cited by 266
Tumor cell plasticity in targeted therapy-induced resistance: Mechanisms and new strategies
Shi, Z.-D., Pang, K., Wu, Z.-X., Dong, Y., Hao, L., Qin, J.-X., Wang, W., Chen, Z.-S., & Han, C.-H. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01383-x · Cited by 256
“demonstrated that most of the phenotypic heterogeneity in melanoma can be explained by the phenotypic plasticity model.(216) Although they did not identify a marker that can significantly distinguish tumorigenic from non-tumorigenic cells, CD271+ cells were shown to have little tumorigenic activity.”
BackgroundCancer stem cell plasticity and tumor hierarchy
Cabrera, M. C. (2015) · World Journal of Stem Cells · doi:10.4252/wjsc.v7.i1.27 · Cited by 252
Cells of origin in osteosarcoma: Mesenchymal stem cells or osteoblast committed cells?
Mutsaers, A. J., & Walkley, C. R. (2014) · Bone · doi:10.1016/j.bone.2014.02.003 · Cited by 233
“The lessons from melanoma suggest that the robust and systematic in vivo analysis of limiting cell transplants coupled with primary tumor material is the only way to identify tumor initiating cells from human tumors [44–47].”
BackgroundPhenotype Switching: Tumor Cell Plasticity as a Resistance Mechanism and Target for Therapy
Kemper, K., de Goeje, P. L., Peeper, D. S., & van Amerongen, R. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1174 · Cited by 216
Cancer Stem Cells and Epithelial-to-Mesenchymal Transition in Cancer Metastasis
Celià-Terrassa, T., & Jolly, M. K. (2020) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a036905 · Cited by 163
The dualistic origin of human tumors
Liu, J. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.07.004 · Cited by 148
Cheng, P. F., Shakhova, O., Widmer, D. S., Eichhoff, O. M., Zingg, D., Frommel, S. C., Belloni, B., Raaijmakers, M. I., Goldinger, S. M., Santoro, R., et al. (2015) · Genome Biology · doi:10.1186/s13059-015-0594-4 · Cited by 100
“In an effort to elucidate the molecular mechanisms of melanoma progression, significant differences have been detected between melanoma cells from the same lesion [4,6,9].”
BackgroundInfluentialThe low affinity neurotrophin receptor CD271 regulates phenotype switching in melanoma
Restivo, G., Diener, J., Cheng, P. F., Kiowski, G., Bonalli, M., Biedermann, T., Reichmann, E., Levesque, M. P., Dummer, R., & Sommer, L. (2017) · Nature Communications · doi:10.1038/s41467-017-01573-6 · Cited by 82
Regression of metastatic melanoma by targeting cancer stem cells
Schlaak, M., Schmidt, P., Bangard, C., Kurschat, P., Mauch, C., & Abken, H. (2012) · Oncotarget · doi:10.18632/oncotarget.437 · Cited by 71
“These tumor-initiating cells may be variable in number and must not necessarily be rare in the case of melanomas [6,7].”
Background
Metadata
- Authors
- Quintana, E., Shackleton, M., Foster, H. R., Fullen, D. R., Sabel, M. S., Johnson, T. M., & Morrison, S. J.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2010-11
- Volume
- 18
- Issue
- 5
- Pages
- 510-523
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W2023457181
- Cited by
- 599
- References
- 36
- FWCI
- 29.49
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.